Featured Latest news

India Approves Novo Nordisk’s Wegovy for Fatty Liver Disease Treatment

By Uniquetimesorg July 18, 2026 0

India’s drug regulator has approved Novo Nordisk’s obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The approval covers the 2.4 mg semaglutide injection and marks another significant milestone for the blockbuster drug, which is already approved in India for chronic weight Continue Reading

Featured Latest News

Dr Reddy’s Shares Tumble as Semaglutide Supply Disruption Raises Growth Concerns

By Uniquetimesorg July 10, 2026 0

Dr Reddy’s Laboratories recorded its worst weekly stock performance in three years after announcing disruptions in the supply of its generic semaglutide drug. The company said production of new batches had been halted due to an impurity issue in the active ingredient, with supplies expected to remain unavailable in India and disrupted in Canada until […]Continue Reading

Featured Latest News

India Tightens Crackdown on Unauthorised Sale of Weight-Loss Drugs After Generic Boom

By Uniquetimesorg March 24, 2026 0

India’s drug regulator has stepped up surveillance against the unauthorised sale and promotion of weight-loss medicines, the health ministry announced on Tuesday, following the launch of cheaper generic versions of blockbuster drugs like Ozempic and Wegovy. Several leading Indian pharmaceutical companies, including Dr Reddy’s, Zydus, and Sun Pharma, have introduced Continue Reading

Featured Latest News

Indian Firms Launch Low-Cost Ozempic, Wegovy Generics

By Uniquetimesorg March 23, 2026 0

Indian pharmaceutical companies have rapidly introduced cheaper versions of Novo Nordisk’s diabetes drug Ozempic and weight-loss drug Wegovy following the expiration of semaglutide’s patent in India. Prices for these generics are about 70% lower than the original, with dozens of brands expected to hit the market as early as this year. Analysts predict over 40 […]Continue Reading

Featured Latest News

Zydus, Lupin Partner to Co-Market Semaglutide Injections Ahead of Patent Expiry

By Uniquetimesorg March 17, 2026 0

Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co-market semaglutide injections in India, positioning themselves ahead of the drug’s upcoming patent expiry. Semaglutide, a GLP-1 receptor agonist, is widely used for treating Type 2 diabetes and has gained popularity for weight management due to its ability to regulate blood sugar […]Continue Reading

Entertainment Featured Latest News

Sun Pharma Wins Approval to Launch Generic Wegovy in India

By Uniquetimesorg January 23, 2026 0

Sun Pharmaceutical Industries, India’s largest drugmaker by revenue, has received regulatory approval to manufacture and sell a generic version of Novo Nordisk’s blockbuster weight-loss drug Wegovy in India, the company said on Friday. The generic drug, semaglutide, will be launched under the brand name Noveltreat after the expiry of Novo Nordisk’s patent in March 2026. Continue Reading

Featured Latest News

Ozempic Launches in India at Rs 2,200/Week for Type-2 Diabetes

By Uniquetimesorg December 12, 2025 0

Danish pharma giant Novo Nordisk has launched its once-weekly semaglutide injection, Ozempic, in India, priced at ₹8,800 for 0.25 mg, ₹10,170 for 0.5 mg, and ₹11,175 for 1 mg, translating to a weekly starting cost of around ₹2,200. Approved as an adjunct to diet and exercise, Ozempic is aimed at adults with type-2 diabetes with […]Continue Reading